{"id":"NCT01425203","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)","officialTitle":"Safety and Efficacy of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for Treatment of Chronic Hepatitis C Genotype 1 in Russia: Previously Untreated Patients and Patients Who Failed Prior Treatment With Pegylated-Interferon Plus Ribavirin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-11-23","primaryCompletion":"2013-10-21","completion":"2013-10-21","firstPosted":"2011-08-29","resultsPosted":"2014-08-18","lastUpdate":"2021-02-08"},"enrollment":238,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hepatitis C Genotype 1"],"interventions":[{"type":"DRUG","name":"Boceprevir","otherNames":["SCH 503034"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"BIOLOGICAL","name":"peginterferon alfa-2b","otherNames":["PegIntron"]},{"type":"DRUG","name":"Ribavirin","otherNames":[]}],"arms":[{"label":"RGT BOC + PR","type":"EXPERIMENTAL"},{"label":"PBO + PR (Control)","type":"PLACEBO_COMPARATOR"},{"label":"Crossover Arm","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine whether Boceprevir (BOC, SCH 503034, MK-3034) in combination with Peginterferon Alfa 2-b (PEG) plus Ribavirin (RBV) \\[PEG+RBV=PR\\] is effective in the treatment of chronic hepatitis C (CHC) genotype 1 among the Russian population. The primary hypothesis is that the percentage of participants achieving sustained virologic response in the BOC + PR group is superior to that in the Placebo (PBO) + PR group.","primaryOutcome":{"measure":"Percentage of Participants Achieving Sustained Virologic Response At Follow-up Week 24 (SVR24) Among Participants Who Received At Least One Dose of Any Trial Medication (Full Analysis Set Population)","timeFrame":"Follow-up Week 24 (up to 72 weeks)","effectByArm":[{"arm":"RGT BOC + PR","deltaMin":74.8,"sd":null},{"arm":"PBO + PR (Control)","deltaMin":46.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":8},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["26962399"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":159},"commonTop":["Neutropenia","Pyrexia","Anaemia","Leukopenia","Dysgeusia"]}}